AKT dependence of ovarian cancer cell lines.

Slides:



Advertisements
Similar presentations
© red ©
Advertisements

Date of download: 6/22/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Reduction of Hyaluronan-CD44–Mediated Growth, Migration,
B A P-AXL P-AXL AXL AXL P-MET P-MET MET MET P-Akt-473 P-Akt-473 AKT
Copyright © 2010 American Medical Association. All rights reserved.
Inhibition of FGFR fusion kinase activity repressed tumor growth in a mouse xenograft model. Inhibition of FGFR fusion kinase activity repressed tumor.
SCLCs and LCNECs are sensitive to PARP inhibition in vitro.
Modulation of KRASG12C activity alters ARS-853 target engagement and supports novel therapeutic strategies for targeting KRAS. A, schematic for altering.
Volume 145, Issue 1, Pages (April 2017)
Lymphoma cells with BCL2/PMAIP1 coamplification are highly sensitive to BCL-2 inhibitor. Lymphoma cells with BCL2/PMAIP1 coamplification are highly sensitive.
Small-molecule inhibitor QLT-0267 suppresses ILK activity and inhibits its downstream signaling. Small-molecule inhibitor QLT-0267 suppresses ILK activity.
NF1 silencing confers resistance of PC9 lung adenocarcinoma cells to erlotinib (erl). NF1 silencing confers resistance of PC9 lung adenocarcinoma cells.
Recombinant OPCML protein effect in vitro.
Combined inhibition of MAP kinase and KIT signaling destabilizes ETV1 protein and results in enhanced growth suppression of human GIST cells. Combined.
Fig. 2. Mutant KRAS mediates resistance to PARPi and sensitivity to PARPi and MEKi Mutant KRAS mediates resistance to PARPi and sensitivity to PARPi and.
Fig. 1. PARPi and MEKi induce inverse adaptive responses.
RAS/RAF pathway-activated ovarian cancer cells exhibit MEK dependence and synergistic induction of apoptosis with combined MEK/AKT inhibition. RAS/RAF.
Suppressive effect of CD39+CD73+ melanoma cells on T-cell proliferation, and reversion of this effect via treatment with the CD39-blocking antibody, CD39.
Supplementary Figure 2. AKT1 AKT1 AKT2 pAKT ERK pERK A1847 A2780 CaOV3
What Color is it?.
NF1 downregulation activates MAPK pathway signaling.
A20 inhibits caspase-8 cleavage and TRAIL-induced apoptosis.
High-throughput combination drug screening to nominate potent drug combinations. High-throughput combination drug screening to nominate potent drug combinations.
PI(3,4,5)P3 releases SIN1-PH–mediated inhibition on mTOR-KD, leading to mTORC2 activation. PI(3,4,5)P3 releases SIN1-PH–mediated inhibition on mTOR-KD,
Signaling induced by BRAF L597R and L597S is sensitive to BRAF and MEK inhibitors. Signaling induced by BRAF L597R and L597S is sensitive to BRAF and MEK.
Glutamine has pleiotropic role of positively regulating respiration and maintaining redox balance selectively in high‐invasive ovarian cancer (OVCA) cells.
Leto et al., Supplementary Figure S3
A and B, CO-1686–resistant NCI-H1975 cell clones, COR1-1 and COR10-1 display a reduced dependence on EGFR signaling for survival. A and B, CO-1686–resistant.
AML cells display differential sensitivity to inhibition of IKBKE and TBK1. AML cells display differential sensitivity to inhibition of IKBKE and TBK1.
Antitumor efficacy of PI3K inhibitor NVP-BKM120 alone and in combination with olaparib. Antitumor efficacy of PI3K inhibitor NVP-BKM120 alone and in combination.
Alterations in the Rap1 and PI3K–Akt signaling in afadin cKO mice.
The effects of the FASN blocker C75 on cell growth and survival (A, E, and F), on expression/phosphorylation of PI3K and MAPK signaling proteins and on.
GA blocks HIF activity and reduces HIF target expression.
Activity of SW480 qHTS runs and podophyllotoxin titration–response profiles of from library and control samples. Activity of SW480 qHTS runs and podophyllotoxin.
PTENP1 sensitizes renal cancer cells to chemotherapy.
Induction of CDCP1 is regulated by Ras in NSCLC cells.
CDDO-Me induces apoptosis independent of Bcl-2 level as well as p53 status in human NSCLC cells. CDDO-Me induces apoptosis independent of Bcl-2 level as.
Greater induction of apoptosis following EGFR TKI treatment correlates with higher basal BIM expression across a panel of EGFR-mutant lung cancers. Greater.
The effect of IAA on tumor growth in an SK-MEL-28 xenograft model.
Pancreatic cancer cell lines are sensitive to knockdown of outlier kinases. Pancreatic cancer cell lines are sensitive to knockdown of outlier kinases.
MiR-200c is a PI3K–AKT signaling pathway regulator in CRC
Discovery of Gö6976-related potent reversible EGFR T790M inhibitors.
MDA-468TR-PTEN (with and without 100 ng/ml doxycycline) and MDA-468TR-vector (with dox) were serum starved overnight and the following day treated for.
The cross-talk between PARylation and phosphorylation.
Changes in signal transduction pathway induced by gefitinib.
KRAS mutation leads to resistance to combined RAF/EGFR and RAF/MEK inhibition. KRAS mutation leads to resistance to combined RAF/EGFR and RAF/MEK inhibition.
Effect of siltuximab on paclitaxel sensitivity in ovarian cancer drug resistant cells. Effect of siltuximab on paclitaxel sensitivity in ovarian cancer.
Untargeted LC/MS metabolite profiling of DFMO-treated HT-29 colorectal cancer cells. Untargeted LC/MS metabolite profiling of DFMO-treated HT-29 colorectal.
Quantitative PTEN protein expression is associated with pertuzumab sensitivity in vitro and trastuzumab resistance in vivo. Quantitative PTEN protein expression.
Combined inhibition of coamplified RTKs is required for response.
BCR/ABL expression, tyrosine phosphorylation, and signaling in dasatinib- and imatinib-resistant cell lines and the ubiquitin inhibitor lactacystin modifies.
Differential effects of the RAF inhibitor PLX4032 in BRAF-mutant melanoma, thyroid, and colorectal cancer cell lines. Differential effects of the RAF inhibitor.
AKT activation in HCC2429 is SRC- but not Notch-dependent.
Effect of MIF siRNA on the production of MMP-13 induced by LPA
Establishment of HeLa/rtTAA/TRE-N1-IC cell line.
Validation of MYC-driven drug responses.
ABT-888 sensitizes multiple ovarian cancer cell lines but not normal cells to FdUrd. ABT-888 sensitizes multiple ovarian cancer cell lines but not normal.
Posttranslational phosphorylation of p53 by platinum drugs in ovarian tumor cells. Posttranslational phosphorylation of p53 by platinum drugs in ovarian.
Crizotinib-resistant NPM-ALK mutants retain sensitivity to ganetespib.
High nuclear β-catenin levels confer resistance to AKT inhibition and coordinates with increased nuclear FOXO3a to promote metastasis in colon cancer.
Mechanism by which flavopiridol induces cell cycle arrest and apoptosis in rhabdoid tumor cells. Mechanism by which flavopiridol induces cell cycle arrest.
Correlations between APOBEC expression and immune cell markers across 22 cancer types. Correlations between APOBEC expression and immune cell markers across.
MTOR kinase inhibition–induced reactivation of AKT substrates is HER2 and PI3K dependent. mTOR kinase inhibition–induced reactivation of AKT substrates.
PTEN genotype frequently dictates PTEN expression status, but evidence of heterogeneous staining implies polyclonality within some ovarian tumors. PTEN.
The ovarian cancer cell lines modestly recapitulate the spectrum of mutations found in primary ovarian tumors. The ovarian cancer cell lines modestly recapitulate.
NVP-BGJ398 inhibits proliferation of a subset of cancer cell lines.
NUAK1 overexpression correlates with tumor progression, lymph node infiltrates, and reduced overall survival (OS) in human colorectal cancer. NUAK1 overexpression.
Driver pathways and key genes in OSCC
Integrated analysis of gene expression and copy number alterations.
Genomic and proteomic profiling of ovarian cancer cell lines.
AXL is not necessary for maintenance of intrinsic resistance.
Presentation transcript:

AKT dependence of ovarian cancer cell lines. AKT dependence of ovarian cancer cell lines. A, IC50 and IC90 values for the AKT1/2 inhibitor (AKTi1/2) and panAKT 1/2/3 inhibitor (MK2206) were calculated after treatment with 0 to 10 μM of each inhibitor for 5 days. Drug concentrations are represented by color block gradations from dark red (0–0.3 μM) to bright red (0.3–1.7 μM), dark pink (1.7–3 μM), pale pink (3-10 μM), and white (>10 μM). Cells with detectable AKT3 expression are indicated by black boxes. Cell lines are colored based on the presence of PI3K/AKT (red) or RAS/RAF-pathway (blue) alterations and RB1 loss (green and green underline) as in Figure 1B. B, cells were treated for 0 to 24 hours with AKTi-1/2 or MK2206 (2 μM) and lysates immunoblotted for p-AKT S473 and total AKT. C, day 5 dose–response plots of three representative cell lines (IGROV-1, hypersensitive to AKT inhibition, red; OVCAR-5, heightened sensitivity to pan-AKT inhibition, blue; SKOV-433, resistant to AKT inhibition, green). Aphrothiti J. Hanrahan et al. Cancer Discov 2012;2:56-67 ©2012 by American Association for Cancer Research